Development of liposomal amphotericin B formulation

References

• Ahmad I., Sarkar A. K., Bachawat B. K. Design of liposomes to improve delivery of amphotericin-B in the treatment of aspergillosis. Molecular Cell Biochemistry 1989; 91: 85–90
   PubMed Web of Science ®Google Scholar
• Ahmad I., Sarkar A. K., Bachawat B. K. Effect of cholesterol in various liposomal compositions on the in-vivo toxicity, therapeutic efficacy and tissue distribution of amphotericin B. Biotechnology and Applied Biochemistry 1990; 12: 550–556
   PubMed Web of Science ®Google Scholar
• Anaissie E. J., Ho D., Paetznick V. Comparative in vitro activities of liposomal amphotericin B and amphotericin B against 104 clinical yeast isolates from a large cancer center. Abstracts of 90th Annual Meeting of American Society of Microbiology, Anaheim, CA, 1990; 19
   Google Scholar
• Anaissie E. J., White M., Uzun O., Singer C, Bodey G. P., Matzke D., Azarnia N., Lopez-Berestein G. Amphotericin B lipid complex (ABLC) versus amphotericin B for treatment of hematogenous and invasive candidiasis. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. American Society of Microbiology, Washington, DC 1995; 330
   Google Scholar
• Atkinson A. J., Jr, Bennett J. E. Amphotericin B pharmacokinetics in humans. Antimicrobial Agents and Chemotherapy 1978; 13: 271–276
   PubMed Web of Science ®Google Scholar
• Berenguer J., Munoz P., Parras F., Fernandez-Beca V. Treatment of deep mycoses with liposomal amphotericin R. European Journal of Clinical Microbiology and Infectious Diseases 1994; 13: 504–507
   PubMed Web of Science ®Google Scholar
• Brajtburg J., Gruda I., Daigle I., Medoff G. Concentration dependent dual effect of the monolauryl ester of sucrose on the antifungal activity and absorbtion spectra of amphotericin B. Biochimica et Biophysica Acta 1986; 33: 362–368
   Google Scholar
• Brajtburg J., Powderly W. G., Kobayashi G. S., Medo G. Amphotericin B: current understanding of mechanisms of action. Antimicrobial Agents and Chemotherapy 1990; 34: 183–188
   PubMed Web of Science ®Google Scholar
• Caillot D., Cassasnovas O., Solary D., Chavanet P., Bonnette B., Reny G. Efficacy and tolerance of an amphotericin B lipid (intralipid) emulsion on the treatment of candidaemia in neutropenic patients. Journal of Antomicrobial Chemotherapy 1993; 31: 161–169
   PubMed Web of Science ®Google Scholar
• Chavanet P., Charlier N., Goux A., Muggeo E., Brenet A., Arthur R. Interaction of intralipide-amphotericine B in vivo. In abstracts of the 11th Reunion Interdisciplinaire de chimiotherapie anti-infectieuse, Paris, 1991; 181, Abs. 220
   Google Scholar
• Chen W., Bittman R. Kinetics of association of amphotericin B with vesicles. Biochemistry 1977; 16: 4145–4149
   PubMed Web of Science ®Google Scholar
• Chopra R., Blair S., Strang J., Patterson K. G., Goldstone A. H. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. Journal of Antimicrobial Chemotherapy 1991; 28: 93–104
   PubMed Web of Science ®Google Scholar
• Chopra R., Fielding A., Goldstone A. H. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin B (AmBisome). Leukemia and Lymphatics 1992; 7: 73–77
   PubMed Web of Science ®Google Scholar
• Christiansen K. J., Bernard E. M., Gold J. W. N., Armstrong D. Distribution and activity of amphotericin B in humans. Journal of Infectious Diseases 1985; 152: 1037–1043
   PubMed Web of Science ®Google Scholar
• Chuk S. L., Sande M. A. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. New England Journal of Medicine 1989; 321: 794–799
   PubMed Web of Science ®Google Scholar
• Clark J. M., Whitney R. R., Olsen S. J., George R. J., Swerdel M. R., Kunselman L. Amphotericin B lipid complex therapy of experimental infections in mice. Antimicrobial Agents and Chemotherapy 1991; 35: 615–621
   PubMed Web of Science ®Google Scholar
• Coker R. J., Viviani M., Gazzard B. G., Dupont B., Pohle H. D., Murphy S. M., Atouguia J., Champalimaud J. L., Harris J. R. W. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993; 7: 829–835
   PubMed Web of Science ®Google Scholar
• Coleman J. M., Hogg G. G., Rosenfeld J. V., Waters K. D. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole and radical surgery-case report and review of the literature. Neurosurgery 1995; 36: 858–863
   PubMed Web of Science ®Google Scholar
• Collette N., van der Auwera P., Meunier F., Lambert C., Sculier J. P., Coune A. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. Antimicrobial Agents and Chemotherapy 1991; 27: 535–548
   Google Scholar
• Croft S. L., Davidson R. N., Thornton E. A. Liposomal amphotericin B in the treatment of visceral leishmaniasis. Journal of Antimicrobial Chemotherapy 1991; 28: 111–118
   PubMed Web of Science ®Google Scholar
• Dornbusch H. J., Urban C. E., Pinter H., Ginter G., Fotter R., Becker H., Miorini T., Berghold C. Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (Ambisome), granulocyte colony-stimulating factor, and surgery: report of five cases. Pediatric Hematology and Oncology 1995; 12: 577–586
   PubMed Web of Science ®Google Scholar
• Dufoure E. J., Smith I. C., Jerrell H. C. Interaction of amphotericin B with membrane lipids as viewed by 2H-NMR. Biophysica et Biochimica Acta 1984; 778: 435–442
   PubMedGoogle Scholar
• Eisenberg E. S., Leviton I., Soeiro R. Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of literature. Reviews on Infectious Diseases 1986; 8: 309–321
   PubMedGoogle Scholar
• Fielding R. M., Smith P. C., Wang L. H., Porter J., Guo L. S. S. Comparative pharmacokinetics of amphotericin B after administration of a novel delivery system, ABCD, and a conventional formulation to rat. Antimicrobial Agents and Chemotherapy 1991; 35: 1208–1211
   PubMed Web of Science ®Google Scholar
• Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B; 30 years of clinical experience. Reviews on Infectious Diseases 1990; 12: 308–326
   PubMedGoogle Scholar
• Gokhale P. C., Kotwani R. N., Dange S. Y., Kshirsagar N. A., Pandiya S. K. Preclinical and pharmaceutical testing of liposomal amphotericin B. Indian Journal of Medical Research 1993; 98: 75–78
   PubMed Web of Science ®Google Scholar
• Gondal J. A., Swartz R. P., Rahman A. Therapeutic Evaluation of free and liposome encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrobial Agents and Chemotherapy 1989; 33: 1544–1548
   PubMed Web of Science ®Google Scholar
• Graybill J. R., Bocanegra R. Liposomal amphotericin B therapy of murine Histoplasmosis. Antimicrobial Agents and Chemotherapy 1995; 39: 1885–1887
   PubMed Web of Science ®Google Scholar
• Graybill J. R., Craven P. C., Taylor R. L., Williams D. M., Magee W. E. Treatment of murine cryptococcosis with liposome associated amphotericin B. Journal of Infectious Diseases 1982; 145: 748–752
   PubMed Web of Science ®Google Scholar
• Heinemann V., Kahny B., Debus A., Wachholz K., Jehn U. Pharmacokinetics of liposomal amphotericin B (Ambisome) versus other lipid-based formulations. Bone Marrow Transplant 1994; 14: S8–9
   Web of Science ®Google Scholar
• Holz R. W. Mechanism of action of antieukaryotic and antiviral compounds. Antibiotics, D. Gottlieb, P. D. Shaw. Springer, New York 1979; vol. 2: 313–340
   Google Scholar
• Hopfer R. L., Mills K., Mehta R., Lopez-Berestein G., Fainstein V., Juliano R. L. In-vitro antifungal activities of amp B and liposomal amphotericin B. Antimicrobial Agents and Chemotherapy 1984; 25: 387–389
   PubMed Web of Science ®Google Scholar
• Hosking M. C., MacDonald N. E., Cornel G. Liposomal amphotericin B for postoperative Aspergillus fumigatus endocarditis. Annals of Thoracic Surgery 1995; 59: 1015–1017
   PubMed Web of Science ®Google Scholar
• Hospenthal D., Gretzinger K., Rogers A. L. Treatment of murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to C. albicans. Journal of Medical Microbiology 1989; 30: 193–197
   PubMed Web of Science ®Google Scholar
• Janoff A. S., Boni L. T., Popescu M. C., Minchey S. Y., Cullis P. R., Madden T. D., Taraschi T., Gruner S. M., Shyamsunder E., Tate M. W., Mendelsohn R., Bonner D. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proceedings of National Academy of Sciences, USA 1988; 85: 6122–6126
   PubMed Web of Science ®Google Scholar
• Joly V., Dromer J., Yen N., Seta N., Molas G., Carbon C. Incorporation of amphotericin B (AmB) into liposomes alters AmB-induced acute nephrotoxicity in rabbits. Journal of Pharmacology and Experimental Therapy 1989; 251: 311–316
   PubMed Web of Science ®Google Scholar
• Juliano R. L., Grant C. W. M., Barker K. R., Kalp M. A. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Molecular Pharmacology 1987; 31: 1–11
   PubMed Web of Science ®Google Scholar
• Juliano R. L., Stamp D. The effect of particle size and charge on the clearance rate of liposomes and liposome encapsulated drugs. Biochemical and Biophysical Research Communications 1975; 63: 651–658
   PubMed Web of Science ®Google Scholar
• Karyotakis N. C., Anaissie E. J. Efficacy of escalating doses of amphotericin B (Ambisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrobial Agents and Chemotherapy 1994; 38: 2660–2662
   PubMed Web of Science ®Google Scholar
• Kirsh R., Goldstein R., Tarlo J., Paris D., Hook J., Hanna N., Bugelski P., Poste G. An emulsion formulation of amptericin B improves the therapeutic index when treating systemic murine candidiasis. Journal of Infectious Diseases 1988; 158: 1065–1070
   PubMed Web of Science ®Google Scholar
• Kotwani R. N., Gokhale P. C., Kshirsagar N. A., Pandiya S. K. Optimizing dosage regimens of liposomal amphotericin B using aspergillus murine model. Indian Journal oj Pharmacology 1996; 28: 88–92
   Google Scholar
• Kraus H. J., Juliano R. L. Interactions of liposome incorporated amphotericin B with kidney clial cell cultures. Molecular Pharmacology 1988; 34: 286–297
   PubMed Web of Science ®Google Scholar
• Kucers A., Bennet N. M. Amphotericin B. the Use of Antibiotics, 4th edn, A. Kucers, N. M. Bennet. J. B. Lippincott, Philadelphia 1987; 1441–1447
   Google Scholar
• Lawrence R. M., Hoeprich P. D., Jagdis F. A., Monji N., Huston A. C., Schaffener C. P. Distribution of doubly radiolabelled amphotericin B methyl ester and Amphotericin B in non human primate, Macaca mulatta. Journal of Antimicrobial Chernotherapy 1980; 6: 241–249
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Bodey G. P., Frankel L. S. Treatment of hepatosplenic candidiasis with liposomal amphotericin B. Journal of Clinical Oncology 1987; 5: 310–317
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M., Reuben J., Juliano R. L., Bodey G. P. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. Journal of Infectious Diseases 1985; 151: 704–710
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Hopfer R. L., Mehta R., Mewra K., Hersh E. M., Juliano R. L. Prophylaxis of Candida albicans infection in neutropenic mice with liposome encapsulated amphotericin B. Antimicrobial Agents and Chemotherapy 1984a; 25: 366–367
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Hopfer R. L., Mehta R., Mehta K., Hersh E. M., Juliano R. L. Treatment of disseminated candiasis in neutropenic mice with liposome encapsulated amphotericin B. Journal of Infectious Diseases 1984b; 3: 278–283
   Google Scholar
• Lopez-Berestein G., Mehta R., Hopfer R. L., Mehta K., Hersh E. M., Juliano R. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Delivery 1983a; 1: 37–42
   PubMedGoogle Scholar
• Lopez-Berestein G., MeIita R., Hopfer R. L., Mills K., Kasi L., Mehta K., In V., Luna M., Hersh E. M., Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. Journal of Infectious Diseases 1983b; 147: 939–945
   PubMed Web of Science ®Google Scholar
• Mehta K., Lopez-Berestein G., Hopfer R. L., Mills K., Juliano R. L. Liposomal amphotricin B is toxic to fungal cells, but not to mammalian cells. Biochimica et Biophysica Acta 1984; 778: 435–442
   PubMedGoogle Scholar
• Mehta R., Mehta K., Lopez-Berestein G., Juliano R. L. Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infection and Immunity 1985; 47: 429–433
   PubMed Web of Science ®Google Scholar
• Meunier F., Prentice H. G., Ringelen O. Liposomal amphotericin B (AmBisome): safety data from phase II/III clinical trial. Journal of Antimicrobial Chemotherapy 1991; 28(suppl. B)73–82
   PubMedGoogle Scholar
• Mills W., Chopra R., Linch D. C., Coldstone A. H. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients. British Journal of Haematology 1994; 86: 754–760
   PubMed Web of Science ®Google Scholar
• Mitsuttake K., Kohno S., Miyazaki Y., Noda T. In vitro and in vivo antifungal activities of liposomal amphotericin B and amphotericin B lipid complex. Mycopathologia 1994; 128: 13–17
   PubMed Web of Science ®Google Scholar
• Moreau P., Milpied N., Fayette N., Ramee J. P., Harousseau J. L. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. Journal of Antimicrobial Chemotherapy 1992; 30: 535–541
   PubMed Web of Science ®Google Scholar
• New R. R. C., Chance M. L., Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. Journal of Antimicrobial Chemotherapy 1981; 8: 371–381
   PubMed Web of Science ®Google Scholar
• New R. R. C., Chance M. L., Thomas S. C., Peters W. The antileishmanial activity of antimonials entrapped in liposomes. Nature 1978; 277: 55–56
   Google Scholar
• Ng T. T. C., Denning D. W. Liposomal amphotericin B (Ambisome) therapy in invasive fungal infections. Archives of Internal Medicine 1995; 155: 1093–1098
   PubMed Web of Science ®Google Scholar
• Nix D. E., Durrence C. W., May J. R. Amphotericin B bladder irrigations. Drug Intelligence and Clinical Pharmacy 1985; 19: 299–300
   Google Scholar
• Patterson T. F., Minter P., Dijkstra J., Szoka F. C., Ryan J. L., Andriole V. T. Treatment of experimental invasive aspergillosis with novel amphotericin B/ cholesterol-sulphate complexes. Journal of Infectious Diseases 1989; 159: 717–724
   PubMed Web of Science ®Google Scholar
• Payne N. I., Cosgrove R. S., Green A. P., Liu L. In-vivo studies of amphotericin B liposomes derived from proliposomes: Effect of formulation on toxicity and tissue disposition of the drug in mice. Journal of Pharmacy and Pharmacology 1987; 39: 24–28
   PubMed Web of Science ®Google Scholar
• Purcell I. F., Corris P. A. Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Thorax 1995; 50: 1321–1323
   PubMed Web of Science ®Google Scholar
• Proffit R. T., Satorius A., Chiang S., Sullivan L., Alder-Moore J. P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Antimicrobial Chemotherapy 1991; 28: 49–61
   PubMed Web of Science ®Google Scholar
• Ragan M., Chapman A. A. A Biochemical Phylogeny of Protists. Academic, London 1978
   Google Scholar
• Ringden O., Meunier F., Tollemar J., Ricci P., Tura S., Kuse E. Efficacy of Amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy 1991; 28: 73–82
   PubMed Web of Science ®Google Scholar
• Saag M. S., Powderly W. G., Cloud G. A., Robinson P., Greico M. H., Sharkey P. K., Thompson S. E., Sugar A. M., Tuazon C. U., Fisher J. P., Hyslop N., Jacobson J. M., Hafner R., Dismukes W. E. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS associated cryptococcal meningitis. New England Journal of Medicine 1992; 326: 83–89
   PubMed Web of Science ®Google Scholar
• Salaki J. S., Louria D. R., Chmel H. Fungal and yeast infections of the central nervous system: a clinical review. Medicine 1984; 63: 108–132
   PubMed Web of Science ®Google Scholar
• Schurman D., Marques B. M., Grunewald T., Pohle H. D., Hahn H., Ruf B. Safety and efficacy of liposomal amphotericin B in treating AIDS associated disseminated cryptococcosis. Journal of Infectious Diseases 1991; 164: 620–622
   PubMed Web of Science ®Google Scholar
• Sculier J. P., Coune A., Meunier F., Brassnne C., Laduron C., Hollaert C., Collette N., Heymans C., Klastersky J. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. European Journal of Cancer and Clinical Oncology 1988; 24: 527–538
   PubMedGoogle Scholar
• Sculier J. P., Bron D., Coune A., Meunier P. Successful treatment with liposomal amphotericin B in two patients with persisting fungemia. European Journal of Chemistry and Microbiology of Infectious Diseases 1989; 8: 903–907
   PubMed Web of Science ®Google Scholar
• Seaman J., Boer C., Wilkinson R., de Jong J. Liposomal amphotericin B (Ambisome) in the treatment of kala-azar under field conditions. Clinical Infectious Diseases 1995; 21: 188–193
   PubMed Web of Science ®Google Scholar
• Sokol-Anderson M. L., Brajtburg J., Medo G. Amphotericin B induced oxidative damage and killing of Candida albicans. Journal of Infectious Diseases 1986a; 154: 76–83
   PubMed Web of Science ®Google Scholar
• Sokol-Anderson M. L., Brajtburg J., Medo G. Sensitivity of Candida albicans to amphotericin B administered as single or fractional doses. Antimicrobial Agents and Chemotherapy 1986b; 29: 701–702
   PubMed Web of Science ®Google Scholar
• Stamm A. M., Dismukes W. E. Current therapy of pulmonary and disseminated fungal diseases. Chest 1983; 83: 911–917
   PubMed Web of Science ®Google Scholar
• Szoka F. C., Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in-vitro fungicidal activity of liposome intercalated amphotericin B. Antimicrobial Agents and Chemotherapy 1987; 31: 421–429
   PubMed Web of Science ®Google Scholar
• Taylor R. L., Williams D. M., Craven P. C., Graybill J. R., Drutz D. J., Magee W. E. Amphotericin B in liposomes: a novel therapy for histoplasmosis. American Review of Respiratory Diseases 1982; 125: 610–611
   PubMedGoogle Scholar
• Tollemar J., Hockerstedt K., Ericzon B. G., Jalanko H., Ringen O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized placebo-controlled study. Transplantation 1995; 59: 45–50
   PubMed Web of Science ®Google Scholar
• Tremblay C., Barza M., Flore C, Szoka F. Efficacy of liposome intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrobial Agents and Chemotherapy 1984; 26: 170–173
   PubMed Web of Science ®Google Scholar
• van Etten E. W. M., Otte-Lambellion M., van Vianen W., Ten Kate M. T., Baskker-Woudenberg I. A. J. M. Biodistribution of AmBisome in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. Antimicrobial Agents and Chemotherapy 1995a; 35: 509–519
   Google Scholar
• van Ewen E. W. M., van Vianen W., Tijhuis R. H. G., Storm G., Bakker-Woudenberg I. A. J. M. Sterically stabilized amphotericin B-liposomes: toxicity and hiodistribution in mice. Journal of Controlled Release 1995b; 37: 123–129
   Web of Science ®Google Scholar
• van Etten E. W. M., Ten Kate M. T., Stearne K. L. E. T., Bakker-Woudenberg I. A. J. M. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity and efficacy in systemic candidiasis in leukopenic mice. Antimicrobial Agents and Chemotherapy 1995c; 39: 1954–1958
   PubMed Web of Science ®Google Scholar
• van Hoogevest P., de Kruijff B. Effect of amphotericin B on cholesterol containing liposomes of egg phosphatidylcholine and didocosenoyl phosphatidyl-choline. A refinement of the model for the formation of pores by amphotericin B in membranes. Biochimica et Biophysica Acta 1978; 511: 397–407
   PubMedGoogle Scholar
• Warnock D. W. Amphotericin B: an introduction. Journal of Antimicrobial Chemotherapy 1991; 28: 27–38
   PubMed Web of Science ®Google Scholar
• Wasan K. M., Lopez-Berestein G. Interaction of liposomal amphotericin B and serum lipoproteins within biological milieu. Journal of Drug Targeting 1994; 2: 373–380
   PubMed Web of Science ®Google Scholar